PARIS--(BUSINESS WIRE)-- Regulatory News: Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO): Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority): Date August 31, 2014 Total number of outstanding shares 31, 490, 644 Total number of voting rights Theoretical number of voting rights: 31, 490, 644 (including treasury shares) Number of real voting rights: 31, 485, 778 (without treasury shares) About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma For more information, visit the website www.onxeo.com CONTACT: Onxeo Judith Greciet, CEO j.greciet@onxeo.com +33 1 45 58 76 00 or Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 or Alize RP Caroline Carmagnol / Sophie Colin caroline@alizerp.com / scolin@alizerp.com +33 6 64 18 99 59 / +33 6 31 13 76 20
Onxeo: Disclosure of total number of voting rights and number of shares in the capital at August 31, 2014
| Source: Onxeo SA